Global Mergers and Acquisitions (M&A) Deals in Pharma 2021 – Thematic Research

Pages: 28 Published: January 31, 2022 Report Code: GDMA-TR-M019AD

The mergers and acquisitions (M&A) deal value in the pharma sector was $191 billion in 2020. It grew by more than 10% in the year 2021. In terms of deal volume, the year 2021 recorded a growth of over 10%. During the same period, oncology accounted for the largest share of deal value and volume. All regions except China and South and Central America reported an increase in deal volume in 2021 as compared to 2020.​

Overview of the global M&A deals in the pharma sector

Overview of the global M&A deals in the pharma sector

For more insights on this report,  download a free report sample

What are the market dynamics in the pharma sector?

Immuno-oncology is one of the fastest growing segments in oncology, with over 60 therapies across five drug classes, either approved or in pre-registration as of January 2022. The development of immune checkpoint inhibitors and CAR-T therapies in a variety of oncology indications has matured and is particularly robust across the US and China.​

Genomics and gene editing technologies, such as CRISPR, have allowed the development of new game-changing treatments. These include gene therapies, oncolytic viruses, oligonucleotides, DNA vaccines, mRNA vaccines, and recombinant vector vaccines. ​While long-touted for their potential to address unmet needs in infectious diseases, mRNA vaccines showed little advancement through clinical development. However, the arrival of COVID-19 saw the rapid development of highly efficacious mRNA vaccines.

In the US, a rare disease is defined as one that affects fewer than 200,000 people, while in Europe it is one that affects less than one in 2,000 people. There may be as many as 7,000 rare diseases. While individual diseases may be rare, the total number of patients is large, with estimates that one in 17 people will suffer from a rare disease. ​This market can be attractive for pharma for several reasons, including shorter development timelines, lower costs for orphan drugs, market exclusivity, and favorable government policies. However, small patient numbers can lead to ineffective clinical trial recruitment. While revenue is generally lower for rare diseases than for traditional therapies, companies can still make a high return on investment with premium pricing.​

Which are the key regions in terms of M&A deal activity in the pharma sector?

The key regions in the mergers and acquisitions deal activity in the pharma sector are North America, Europe, China, South & Central America, the Middle East & Africa, and APAC Ex-China. North America had the highest value of deals in the year 2021 followed by Europe, APAC, China, Middle East & Africa, and South & Central America.

Global M&A deals in the pharma sector, by region

Global M&A deals in the pharma sector, by region

For more regional insights,  download a free report sample

What are the key sub-sectors in M&A deal activity in the global pharma sector?

The key sub-sectors in the mergers and acquisitions deal activity in the pharma sector are oncology, immunology, infectious disease, cardiovascular, central nervous system, ophthalmology, metabolic disorders, respiratory, dermatology, and gastrointestinal.

Global M&A deals in the pharma sector, by sub-sector

Global M&A deals in the pharma sector, by sub-sector

For more sub-sector insights,  download a free report sample

What are the biggest themes that are driving global M&A deals in the pharma sector?

Rare diseases, genomics, and immuno-oncology are the top 3 themes driving global M&A deals in the pharma sector. Empowered patient, geopolitics, regenerative medicine, demographic changes, strategic alliances, Big Data, wearable technology, drug pricing and reimbursement, outsourcing, cybersecurity, remote patient monitoring, rare disease, artificial intelligence, biosimilars, regulatory changes, immuno-oncology, genomics, and precision & personalized medicine are the biggest themes that will drive the global M&A deals in the pharma sector during the forecast period.

Which were the key companies in the global M&A deals landscape in the banking and payments sector?

The key companies involved in M&A deals in the banking and payments sector in 2021 were Novo Nordisk, Merck & Co, Perrigo Co, Sanofi, Pfizer, EQRx, Bayer, Amgen, PerkinElmer, Vitrolife, Danaher, MorphoSys, Thermo Fisher Scientific, ICON, and Jazz Pharmaceuticals.

Global M&A deals in the pharma sector, by company

Global M&A deals in the pharma sector, by company

To know more about key companies,  download a free report sample

Market Report Scope

Deal Value (2020) $191 billion
Key regions North America, Europe, China, South and Central America, Middle East and Africa, and APAC Ex-China.
Key themes Empowered Patient, Geopolitics, Regenerative Medicine, Demographic Changes, Strategic Alliances, Big Data, Wearable Technology, Drug Pricing & Reimbursement, Outsourcing, Cybersecurity, Remote Patient Monitoring, Rare Disease, Artificial Intelligence, Biosimilars, Regulatory Changes, Immuno-Oncology, Genomics, and Precision & Personalized Medicine
Key sub-sectors Oncology, Immunology, Infectious Disease, Cardiovascular, Central Nervous System, Ophthalmology, Metabolic Disorders, Respiratory, Dermatology, and Gastrointestinal
Key companies Novo Nordisk, Merck & Co, Perrigo Co, Sanofi, Pfizer, EQRx, Bayer, Amgen, PerkinElmer, Vitrolife, Danaher, MorphoSys, Thermo Fisher Scientific, ICON, and Jazz Pharmaceuticals.

Scope

This report provides an overview of merger and acquisition activity globally in 2021 in the pharma sector. It identifies the themes driving most notable to deals announced in 2021 in the pharma sector.

Key Highlights

M&A deal value in global Pharma sector grew by 15%, from $191 billion in 2020 to $219 billion in 2021. In terms of deal volume, 2021 saw 908 deals compared to 795 in the previous year, recording a growth of 14%. There were 44 billion-dollar-plus M&A deals in the pharma sector in 2021, compared to 28 in the previous year.

Reasons to Buy

Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive industry, simply look at the list of recent mergers and acquisitions (M&A). In this report, we have listed the most notable deals in the pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.

Key Players

Novo Nordisk
Merck & Co
Perrigo Co
Sanofi
Pfizer
EQRx
Bayer
Amgen
PerkinElmer
Vitrolife
Danaher
MorphoSys
Thermo Fisher Scientific
ICON
Jazz Pharmaceuticals
Horizon Therapeutics
Dicerna Pharmaceuticals
Acceleron Pharma
Laboratoire HRA Pharma
Kadmon Holdings
Trillium Therapeutics
CM Life Sciences III
Vividion Therapeutics
Translate Bio
TeneoBio
Biolegend
Igenomix
Aldevron
Constellation Pharmaceuticals
PPD
Five Prime Therapeutics
Pandion Therapeutics
PRA Health Sciences
GW Pharmaceuticals
Viela Bio
Kymab
Laboratory Corp of America
Novartis
Synthetic Biologics
Pacira BioSciences
ProPhase Labs
XOMA
UniQure
Brooklyn ImmunoTherapeutics
Nexturn Bio
XERIS Pharmaceuticals
Roivant Sciences
Royalty Pharma
Renovacor
Intec Pharma
VG Acquisition
Ensysce Biosciences
Personal Genome Diagnostics
Gyroscope Therapeutics
VCN Biosciences
Flexion Therapeutics
Nebula Genomics
Kuros Biosciences
Corlieve Therapeutics
Novellus Therapeutics
RosVivo Therapeutics
Strongbridge Biopharma
Montes Archimedes
Tidal Therapeutics
Chardan Healthcare Acquisition
Decoy Biosystems
23andMe
CSL
StepStone Group
Triley Bidco
Murano Bidco
Amunix Operating
Vifor Pharma
Arena Pharmaceuticals
Clinigen Group
CM Life Sciences III
Vectura Group
Vaccitech
Sagard Holdings
Beijing Pharmaceutical Investment and Management
Catalent
Compass Therapeutics
Athenex
Takeda Pharmaceutical
Grifols
Celularity
Avidea Technologies
AnaptysBio
Immunotech Biopharm
RheinCell Therapeutics
TRIGR Therapeutics
Kuur Therapeutics
Montes Archimedes Acquisition
Maverick Therapeutics
GigaGen
Silicon Therapeutics
GX Acquisition

Table of Contents

Global M&A deals in 2021 – Key takeaways

Review of global M&A deals in 2021

Themes driving global M&A deals in 2021

Appendices

Frequently Asked Questions

The key regions in the mergers and acquisitions deal activity in the pharma sector are North America, Europe, China, South & Central America, the Middle East & Africa, and APAC Ex-China.

 

 

 

 

Rare diseases, genomics, and immuno-oncology are the top 3 themes driving global M&A deals in the pharma sector. Empowered patient, geopolitics, regenerative medicine, demographic changes, strategic alliances, Big Data, wearable technology, drug pricing and reimbursement, outsourcing, cybersecurity, remote patient monitoring, rare disease, artificial intelligence, biosimilars, regulatory changes, immuno-oncology, genomics, and precision & personalized medicine are the biggest themes that will drive the global M&A deals in the pharma sector in the future.

The key sub-sectors in the mergers and acquisitions deal activity in the pharma sector are oncology, immunology, infectious disease, cardiovascular, central nervous system, ophthalmology, metabolic disorders, respiratory, dermatology, and gastrointestinal.

The key companies involved in M&A deals in the banking and payments sector in 2021 were Novo Nordisk, Merck & Co, Perrigo Co, Sanofi, Pfizer, EQRx, Bayer, Amgen, PerkinElmer, Vitrolife, Danaher, MorphoSys, Thermo Fisher Scientific, ICON, and Jazz Pharmaceuticals.

$495

Can be used by individual purchaser only

$995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022